An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)

This is an observational safety study tracking real-world outcomes for patients with ulcerative colitis (UC) who are taking tofacitinib, a medication used to control UC symptoms. The study collects data through an existing European patient registry rather than testing a new treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of ulcerative colitis - You are enrolled in the UR-CARE registry in the European Union with at least 12 months of medical history on record - You have signed informed consent - You are starting tofacitinib as your treatment **You may NOT be eligible if...** - You have a history of Crohn's disease or unspecified inflammatory bowel disease in the registry records - You do not meet the inclusion criteria above Talk to your doctor to see if this trial is right for you.